Brookstone Capital Management Amgen Inc Transaction History

Brookstone Capital Management

$6.01 Billion
Q3 2024

A detailed history of Brookstone Capital Management transactions in Amgen Inc stock. As of the latest transaction made, Brookstone Capital Management holds 17,790 shares of AMGN stock, worth $5.62 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

17,790

Previous 16,576 7.32%

Holding current value

$5.62 Million

Previous $5.18 Million 10.68%

% of portfolio

0.1%

Previous 0.1%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$309.38 - $337.38 $375,587 - $409,579	1,214 Added 7.32%	17,790 $5.73 Million
Q2 2024 Jul 18, 2024	BUY	$262.75 - $319.31 $2.19 Million - $2.67 Million	8,350 Added 101.51%	16,576 $5.18 Million
Q1 2024 Apr 15, 2024	SELL	$268.87 - $324.56 $12.3 Million - $14.9 Million	-45,873 Reduced 84.79%	8,226 $2.34 Million
Q4 2023 Jan 11, 2024	SELL	$255.7 - $288.46 $1.56 Million - $1.76 Million	-6,101 Reduced 10.13%	54,099 $15.6 Million
Q3 2023 Oct 20, 2023	SELL	$218.65 - $271.46 $1.82 Million - $2.26 Million	-8,331 Reduced 12.16%	60,200 $16.2 Million
Q2 2023 Jul 11, 2023	BUY	$214.27 - $253.37 $798,155 - $943,803	3,725 Added 5.75%	68,531 $15.2 Million
Q1 2023 Apr 18, 2023	BUY	$225.79 - $275.2 $13 Million - $15.8 Million	57,482 Added 784.84%	64,806 $15.7 Million
Q4 2022 Jan 09, 2023	SELL	$229.03 - $291.01 $9.18 Million - $11.7 Million	-40,089 Reduced 84.55%	7,324 $0
Q3 2022 Oct 13, 2022	BUY	$224.46 - $253.15 $757,552 - $854,381	3,375 Added 7.66%	47,413 $11.7 Million
Q2 2022 Jul 11, 2022	BUY	$230.71 - $256.74 $2.9 Million - $3.23 Million	12,570 Added 39.95%	44,038 $10.9 Million
Q1 2022 Apr 12, 2022	BUY	$219.27 - $242.57 $993,512 - $1.1 Million	4,531 Added 16.82%	31,468 $7.89 Million
Q4 2021 Jan 11, 2022	BUY	$198.88 - $227.6 $4.11 Million - $4.7 Million	20,659 Added 329.07%	26,937 $6.12 Million
Q3 2021 Nov 03, 2021	SELL	$212.27 - $248.7 $331,778 - $388,718	-1,563 Reduced 19.93%	6,278 $1.28 Million
Q2 2021 Jul 14, 2021	BUY	$233.58 - $259.14 $726,900 - $806,443	3,112 Added 65.81%	7,841 $1.92 Million
Q1 2021 Apr 16, 2021	SELL	$221.91 - $258.6 $107,182 - $124,903	-483 Reduced 9.27%	4,729 $1.18 Million
Q4 2020 Jan 13, 2021	SELL	$216.38 - $257.67 $107,973 - $128,577	-499 Reduced 8.74%	5,212 $1.2 Million
Q3 2020 Oct 13, 2020	BUY	$234.65 - $260.95 $318,185 - $353,848	1,356 Added 31.14%	5,711 $1.45 Million
Q2 2020 Jul 21, 2020	SELL	$197.81 - $242.74 $487,601 - $598,354	-2,465 Reduced 36.14%	4,355 $1.03 Million
Q1 2020 Apr 14, 2020	SELL	$182.24 - $241.7 $435,735 - $577,904	-2,391 Reduced 25.96%	6,820 $1.38 Million
Q4 2019 Jan 29, 2020	SELL	$189.21 - $243.2 $308,033 - $395,929	-1,628 Reduced 15.02%	9,211 $2.22 Million
Q3 2019 Oct 18, 2019	SELL	$174.11 - $208.62 $500,218 - $599,365	-2,873 Reduced 20.95%	10,839 $2.1 Million
Q2 2019 Jul 25, 2019	BUY	$166.7 - $195.41 $1.88 Million - $2.2 Million	11,262 Added 459.67%	13,712 $2.53 Million
Q1 2019 Apr 18, 2019	SELL	$180.87 - $203.88 $180,508 - $203,472	-998 Reduced 28.94%	2,450 $466,000
Q4 2018 Feb 06, 2019	SELL	$178.4 - $208.25 $802,621 - $936,916	-4,499 Reduced 56.61%	3,448 $671,000
Q3 2018 Nov 05, 2018	SELL	$185.29 - $208.89 $20,011 - $22,560	-108 Reduced 1.34%	7,947 $1.65 Million
Q2 2018 Aug 06, 2018	BUY	$166.05 - $186.51 $634,809 - $713,027	3,823 Added 90.34%	8,055 $1.49 Million
Q1 2018 Apr 23, 2018	BUY	$169.43 - $198.0 $63,197 - $73,854	373 Added 9.67%	4,232 $721,000
Q4 2017 Feb 07, 2018	SELL	$168.79 - $188.59 $56,713 - $63,366	-336 Reduced 8.01%	3,859 $671,000
Q3 2017 Oct 31, 2017	SELL	$167.29 - $191.0 $60,893 - $69,524	-364 Reduced 7.98%	4,195 $782,000
Q2 2017 Aug 08, 2017	BUY	N/A	4,559	4,559 $785,000

Others Institutions Holding AMGN

# of Institutions

3,073

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookstone Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Brookstone Capital Management with notifications on news.

Account

Brookstone Capital Management Amgen Inc Transaction History